With prospects of an early, accelerated approval for Roche's Alzheimer's disease candidate gantenerumab looking diminished, the drugmaker has launched a new four-year trial in the hope of b
Biogen and Eisai head towards the end of the year with some much-needed good news in their Alzheimer's programmes, as the FDA awards a fast-track designation to lecanemab, their follow-up t
Biogen and Eisai's first Alzheimer's disease drug Aduhelm is facing an uphill battle in the US market, but the partners are forging ahead with their second candidate lecanemab, starting a r